Telix Pharmaceuticals 과거 수익 실적
과거 기준 확인 3/6
Telix Pharmaceuticals has been growing earnings at an average annual rate of 6.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 80.1% per year. Telix Pharmaceuticals's return on equity is 12.2%, and it has net margins of 7.6%.
주요 정보
6.6%
수익 성장률
9.9%
EPS 성장률
| Biotechs 산업 성장 | 17.0% |
| 매출 성장률 | 80.1% |
| 자기자본 수익률 | 12.2% |
| 순이익 | 7.6% |
| 최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
Telix Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 646 | 49 | 175 | 164 |
| 31 Mar 24 | 576 | 32 | 153 | 145 |
| 31 Dec 23 | 503 | 5 | 134 | 129 |
| 30 Sep 23 | 430 | -21 | 102 | 126 |
| 30 Jun 23 | 357 | -48 | 92 | 105 |
| 31 Mar 23 | 249 | -77 | 89 | 91 |
| 31 Dec 22 | 160 | -104 | 87 | 81 |
| 30 Sep 22 | 94 | -111 | 83 | 63 |
| 30 Jun 22 | 29 | -119 | 79 | 45 |
| 31 Mar 22 | 18 | -100 | 63 | 40 |
| 31 Dec 21 | 8 | -81 | 47 | 34 |
| 30 Sep 21 | 7 | -70 | 39 | 31 |
| 30 Jun 21 | 7 | -59 | 32 | 28 |
| 31 Mar 21 | 6 | -52 | 28 | 26 |
| 31 Dec 20 | 5 | -45 | 24 | 23 |
| 30 Sep 20 | 4 | -40 | 22 | 23 |
| 30 Jun 20 | 3 | -36 | 19 | 22 |
| 31 Mar 20 | 3 | -32 | 17 | 22 |
| 31 Dec 19 | 3 | -28 | 16 | 21 |
| 30 Sep 19 | 3 | -23 | 14 | 21 |
| 30 Jun 19 | 2 | -19 | 12 | 20 |
| 31 Mar 19 | 1 | -16 | 11 | 19 |
| 31 Dec 18 | 0 | -14 | 9 | 19 |
| 30 Sep 18 | 0 | -12 | 8 | 14 |
| 30 Jun 18 | 0 | -10 | 7 | 9 |
| 31 Mar 18 | 0 | -8 | 5 | 6 |
| 31 Dec 17 | 0 | -6 | 4 | 3 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
양질의 수익: TLPP.F has high quality earnings.
이익 마진 증가: TLPP.F became profitable in the past.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: TLPP.F has become profitable over the past 5 years, growing earnings by 6.6% per year.
성장 가속화: TLPP.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
수익 대 산업: TLPP.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
자기자본 수익률
높은 ROE: TLPP.F's Return on Equity (12.2%) is considered low.